Israeli authorities said on Sunday that minors aged 5 to 11 will now be eligible for the weaker dosing of the Pfizer COVID-19 vaccine after a majority of experts on its advisory committee voted in favor of the vaccine’s safety profile.
The decision, announced by Israel’s Health Ministry, cited Pfizer’s clinical trial data, which the company says indicates a 90.7 percent efficacy in preventing illness in the age group.
